Literature DB >> 10737579

Extent of surgery for intermediate-risk well-differentiated thyroid cancer.

S Beenken1, D Roye, H Weiss, M Sellers, M Urist, A Diethelm, H Goepfert.   

Abstract

BACKGROUND: Methods of assigning patients with papillary or follicular thyroid cancer (well-differentiated thyroid cancer) to risk groups for the purpose of determining appropriate therapy have been developed. Despite these efforts, the optimal extent of surgery for intermediate-risk patients remains controversial.
METHODS: A retrospective study was conducted of 208 patients with well-differentiated thyroid cancer (DTC) from two institutions. Univariate and multivariate analysis of patient- and tumor-related variables was performed. A regression model was obtained, three risk groups (low, intermediate, and high) were defined, and survival curves were generated.
RESULTS: Prognostic variables were age (P <0.001), distant metastases (P <0.001), tumor size (P <0.001) and an aggressive growth pattern (P = 0.03) by univariate analysis and age (P <0.001) and distant metastases (P <0.001) by multivariate analysis. Tumor size (P = 0.07) was included in the regression model. Total thyroidectomy appeared to provide a survival advantage for intermediate risk patients. High-risk patients treated by lobectomy had a poorer prognosis.
CONCLUSIONS: Total thyroidectomy may provide a survival advantage for intermediate-risk patients with DTC. A prospective randomized trial with 200 such patients is required to confirm this finding.

Entities:  

Mesh:

Year:  2000        PMID: 10737579     DOI: 10.1016/s0002-9610(99)00254-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  18 in total

1.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

Review 2.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

3.  Cancer: QTNM: a simplified TNM or just another staging system?

Authors:  Brian H H Lang; Chung-Yau Lo
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

4.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

5.  Gasless video-assisted total thyroidectomy in the treatment of low risk intrathyroid papillary carcinoma.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

Review 6.  Optimal differentiated thyroid cancer management in the elderly.

Authors:  Donald S A McLeod; Kelly Carruthers; Dev A S Kevat
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

Review 7.  Staging systems for papillary thyroid carcinoma: a review and comparison.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

8.  The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases.

Authors:  Eleni I Efremidou; Michael S Papageorgiou; Nikolaos Liratzopoulos; Konstantinos J Manolas
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

9.  Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Authors:  Brian Hung-Hin Lang; Sin-Ming Chow; Chung-Yau Lo; Stephen C K Law; King-Yin Lam
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

10.  Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.

Authors:  Christian Passler; Gerhard Prager; Christian Scheuba; Klaus Kaserer; Georg Zettinig; Bruno Niederle
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.